NCT05055154 is a NA clinical trial of Very low calorie diet in Obesity, sponsored by Special Hospital for Extended Treatment of Duga Resa.

Who is sponsoring NCT05055154?

NCT05055154 is sponsored by Special Hospital for Extended Treatment of Duga Resa.

What drugs are being tested in NCT05055154?

Interventions in NCT05055154: Very low calorie diet.

What condition does NCT05055154 study?

NCT05055154 studies Obesity, Weight Loss, DNA Damage.

Is NCT05055154 still recruiting?

NCT05055154 is currently completed. Last updated 24 September 2021.

Last reviewed 2021-09-24 · How we verify

NCT05055154

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxidative Stress and L-CBMN Cytome Assay in Obese After 3 Weeks VLCD

Completed NA Last updated 24 September 2021

What this trial tests

NA trial testing Very low calorie diet in Obesity in 26 participants. Completed in 3 November 2020.

Timeline

14 June 2019

Primary endpoint
3 November 2020

3 November 2020

Quick facts

Lead sponsor	Special Hospital for Extended Treatment of Duga Resa
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	14 June 2019
Primary completion	3 November 2020
Estimated completion	3 November 2020
Sites	1 location across Croatia

Drugs / interventions tested

Very low calorie diet

Conditions studied

Obesity — all drugs for Obesity →
Weight Loss — all drugs for Weight Loss →
DNA Damage — all drugs for DNA Damage →

Sponsor

Special Hospital for Extended Treatment of Duga Resa

Who can join

Adults 18 to 70, any sex, with Obesity or Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity leads to physiological imbalance resulting in hyperglycemia, dyslipidaemia and inflammation and can generate systematic oxidative stress through multiple biochemical mechanisms. Oxidative stress (OS) can induce DNA damage and inhibit DNA repair mechanisms. Very low calorie diet (VLCD) have rapid positive effect on weight loss, glucose homeostasis, insulin resistance, inflammation and OS. The aim of this study is to determine the effect of a three-week VLCD on anthropometric, biochemical and genomic parameters in individuals with BMI ≥ 35kg/m2.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of a 3-Week Hospital-Controlled Very-Low-Calorie Diet in Severely Obese Patients.
Ožvald I, Božičević D, Duh L, Vinković Vrček I, et al · · 2021 · cited 6× · PMID 34960018 · DOI 10.3390/nu13124468
Combined Approach: FFQ, DII, Anthropometric, Biochemical and DNA Damage Parameters in Obese with BMI ≥ 35 kg m<sup>-2</sup>.
Milić M, Ožvald I, Matković K, Radašević H, et al · · 2023 · cited 2× · PMID 36839257 · DOI 10.3390/nu15040899

Verify or expand the search:

Other trials of Very low calorie diet

Trials testing the same drug.

NCT05007171 — Changes in Anthropometric, Biochemical and DNA Damage Parameters After 3-weeks VLCD in Severely Obese Patients · NA · completed
NCT03553849 — Utilization of Very Low Calorie Diet in Obese General Surgery Patients · NA · completed
NCT00627484 — Changes in Insulin Sensitivity After Weight Loss · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Special Hospital for Extended Treatment of Duga Resa trials

Trials by the same sponsor.

NCT05007171 — Changes in Anthropometric, Biochemical and DNA Damage Parameters After 3-weeks VLCD in Severely Obese Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05055154 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Special Hospital for Extended Treatment of Duga Resa
Last refreshed: 24 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing